GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD

医学 兴奋剂 恶化 胰高血糖素样肽1受体 内科学 炎症性肠病 药方 克罗恩病 受体 胃肠病学 内分泌学 疾病 药理学
作者
Irving Levine,Shaina Sekhri,William Schreiber-Stainthorp,Brandon Locke,Olivia Delau,M. F. S. El-Hawary,Krutika Pandit,Xucong Meng,Jordan E. Axelrad
出处
期刊:Inflammatory Bowel Diseases [Oxford University Press]
被引量:1
标识
DOI:10.1093/ibd/izae250
摘要

Abstract Background In patients with inflammatory bowel disease (IBD), multimorbidity with obesity and type 2 diabetes is common and increasing. Glucagon-like peptide 1 (GLP-1) receptor agonists are increasingly being prescribed for patients with IBD, yet their impact on patients with IBD is largely unknown. We aimed to assess the impact of GLP-1 receptor agonists on the course of IBD. Methods We identified all IBD patients prescribed GLP-1 receptor agonists at a large academic healthcare network between 2009 and 2023. We analyzed demographics and IBD characteristics in the year pre- and post–GLP-1 receptor agonist prescription and matched them to non-IBD controls. Our primary outcome was IBD exacerbation in the year following GLP-1 receptor agonist initiation, measured as a composite of IBD-related hospitalization, corticosteroid prescription, medication escalation or changes, or IBD-related surgery. Secondary outcomes included change in metabolic risk factors. Results Overall, 224 patients met inclusion criteria. At GLP-1 receptor agonist initiation, the median age was 54 years, 63% were female, 77% were White, and median BMI was 33.2 kg/m2. Compared to the 12-month period prior to GLP-1 receptor agonist initiation, in the 12 months post–GLP-1 receptor agonist initiation, there was no change in rates of IBD exacerbation, IBD-related hospitalization, steroids prescription, medication escalation or changes, or IBD-related surgery. There was a significant decrease in BMI in the year following GLP-1 receptor agonist initiation (median BMI 33.5 vs 31.6 kg/m2, P < .01), with rates of decrease comparable to non-IBD matched controls. Conclusions In patients with IBD, GLP-1 receptor agonists are effective for weight loss and associated with few episodes of disease exacerbation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
陈少华完成签到 ,获得积分10
刚刚
下一秒发布了新的文献求助10
1秒前
杨乃彬完成签到,获得积分10
1秒前
取名叫做利完成签到,获得积分10
2秒前
赘婿应助喻义梅采纳,获得10
3秒前
小二郎应助小门采纳,获得10
4秒前
ll发布了新的文献求助10
7秒前
正直的鸿完成签到,获得积分10
12秒前
13秒前
万能图书馆应助高贵梦露采纳,获得10
14秒前
momo发布了新的文献求助10
16秒前
传奇3应助boltos采纳,获得10
17秒前
17秒前
18秒前
要减肥笑阳完成签到 ,获得积分10
19秒前
全若之发布了新的文献求助10
24秒前
Jasper应助momo采纳,获得10
26秒前
Kasom完成签到 ,获得积分10
33秒前
顺利一德完成签到,获得积分20
34秒前
香蕉觅云应助Afaq采纳,获得10
34秒前
34秒前
34秒前
manman完成签到,获得积分10
35秒前
35秒前
哈哈哈完成签到,获得积分10
35秒前
YamDaamCaa应助科研通管家采纳,获得30
36秒前
36秒前
领导范儿应助科研通管家采纳,获得10
36秒前
香蕉觅云应助科研通管家采纳,获得10
36秒前
36秒前
大个应助科研通管家采纳,获得10
36秒前
czh应助科研通管家采纳,获得20
36秒前
科研通AI2S应助科研通管家采纳,获得10
36秒前
酷波er应助科研通管家采纳,获得10
36秒前
纯情的天奇完成签到 ,获得积分10
38秒前
顺利一德发布了新的文献求助10
39秒前
潇湘雪月发布了新的文献求助10
39秒前
39秒前
胡萝卜发布了新的文献求助10
40秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989263
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253814
捐赠科研通 3270066
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882084
科研通“疑难数据库(出版商)”最低求助积分说明 809136